JanaPortnowMD

Clinical Trials

• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01

  Active, not recruiting

  Phase 3

• High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Jul 12

  Completed

  Phase 2

• Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Start of enrollment: 2005 Jan 01

  Completed

  Phase 1

• Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors Start of enrollment: 2006 Jan 01

  Completed

  Phase 1

• Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma Start of enrollment: 2008 Apr 01

  Completed

  Phase 1

• A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Start of enrollment: 2008 Jun 01

  Completed

  Phase 1

• Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01

  Completed

  Phase 3

• A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma Start of enrollment: 2010 Jul 01

  Completed

  Phase 1

• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Start of enrollment: 2010 Aug 01

  Completed

  Phase 1

• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Start of enrollment: 2010 Dec 01

  Completed

  Phase 1

• Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2014 Feb 01

  Terminated

  Phase 2

• Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Start of enrollment: 2014 Mar 01

  Completed

  Phase 2

• Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Start of enrollment: 2014 Oct 07

  Completed

  Phase 1

• Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Start of enrollment: 2016 Mar 07

  Active, not recruiting

  Phase 1

• HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Start of enrollment: 2018 Aug 31

  Recruiting

  Phase 1

• Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08

  Active, not recruiting

  Not Applicable

  Roles: Contact

• Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors Start of enrollment: 2022 Apr 09

  Active, not recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas Start of enrollment: 2023 May 02

  Recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma Start of enrollment: 2024 Aug 15

  Not yet recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• Join now to see all